Fair selection of participants in clinical trials: The challenge to push the envelope further

The pipeline of new drugs being developed for cystic fibrosis (CF) is both exciting and challenging, perhaps in equal measure. Issues related to the large number of trials being conducted, some of these competing for the same group of patients, the need to ensure that more traditional drugs such as anti-infectives/ anti-inflammatories can still be trialled whilst CFTR modulators are ‘stealing the show’ and the inequity of access remain paramount. The CF Foundation's Therapeutic Development Network (TDN) and the European CF Society Clinical Trials Network (ECFS CTN) are actively engaged in tackling these issues and the ECFS Task Force's strategic plan to speed up access to m edicines has recently published its first papers proposing solutions related to trial design [1] and rare mutations [2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Letter to the Editor Source Type: research